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Abstract
Background
The family Flaviviridae, genus Flavivirus, holds many of the world’s most prevalent arboviral
diseases that are also considered the most important travel related arboviral infections. In
most cases, flavivirus diagnosis in travelers is primarily based on serology as viremia is
often low and typically has already been reduced to undetectable levels when symptoms
set in and patients seek medical attention. Serological differentiation between flaviviruses
and the false-positive results caused by vaccination and cross-reactivity among the different
species, are problematic for surveillance and diagnostics of flaviviruses. Their partially over-
lapping geographic distribution and symptoms, combined with increase in travel, and preex-
isting antibodies due to flavivirus vaccinations, expand the need for rapid and reliable
multiplex diagnostic tests to supplement currently used methods.
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Goal
We describe the development of a multiplex serological protein microarray using recombi-
nant NS1 proteins for detection of medically important viruses within the genus Flavivirus.
Sera from clinical flavivirus patients were used for primary development of the
protein microarray.
Results
Results show a high IgG and IgM sensitivity and specificity for individual NS1 antigens, and
limited cross reactivity, even within serocomplexes. In addition, the serology based on this
array allows for discrimination between infection and vaccination response for JEV vaccine,
and no cross-reactivity with TBEV and YFV vaccine induced antibodies when testing for an-
tibodies to other flaviviruses.
Conclusion
Based on these data, multiplex NS1-based protein microarray is a promising tool for surveil-
lance and diagnosis of flaviviruses.
Author Summary
The number of international travelers has increased dramatically in recent decades. This
has contributed to the increase in infectious diseases in travelers which are not present in
their countries of origin and so may cause a threat to the public health. Viruses transmitted
by biting insects (vector-borne viruses) are an important group within these travel-related
diseases. They are found across the world and can cause debilitating and life-threatening
symptoms, like inflammation of the brain or excessive bleeding. Many of these diseases are
difficult to distinguish from each other. They cause comparable symptoms and are geneti-
cally closely related. Testing for long lists of diseases is time consuming and expensive.
Here we develop a novel testing tool that allows doctors and researchers to test for multiple
viruses with just one test. The method, which uses a specific part of the virus that makes
distinguishing between infections with these closely related viruses possible, requires only
one drop of blood. This allows us to test for multiple viruses simultaneously with the same
amount of blood previously used to test for only one virus, while distinguishing between
genetically closely related viruses.
Introduction
The family Flaviviridae, genus Flavivirus, holds many of the world’s most prevalent arboviral
diseases that are also considered the most important travel related arboviral infections.[1] As
the geographic distribution and symptoms caused by these viruses overlap, detection requires
differential diagnostic algorithms that include multiple flaviviruses.[2] Increase in travel ex-
pands the need for rapid and reliable multiplex diagnostic tests in non-endemic countries to
supplement currently used methods.[3, 4]
Flaviviruses are single stranded enveloped viruses with an RNA genome of about 11 kb
length. The genome is composed of three structural (Envelope, Capsid and Precursor-
membrane) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and
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NS5).[5] Diagnosis is primarily based on serology through detection of IgM and IgG antibod-
ies, as viremia typically has been reduced to undetectable levels when symptoms set in and pa-
tients seek medical attention.[5–7]
The genus is divided into serocomplexes that are distinguished based on neutralizing anti-
body reactivity (Fig. 1). The amino acid homology of the envelope (E) protein (which is the
immunodominant antigen for neutralizing antibody assays) ranges from 40–50% between ser-
ocomplexes and 70–80% for virus species within a serocomplex.[5, 8] Antibodies to flaviviruses
are known to cross-react extensively within, and to a certain extent between, serocomplexes
when using traditional antibody assays.[9–12] Cross-reactivity occurs also if patients have been
Fig 1. The serogroup classification of the Flavivirus genus of arboviruses used. Shaded boxes indicate antigens and antibodies used in this validation.
Viruses with an * indicate that human vaccines are available for this virus.
doi:10.1371/journal.pntd.0003580.g001
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vaccinated against flaviviruses such as yellow fever virus (YFV), tick-borne encephalitis virus
(TBEV) and/or Japanese encephalitis virus (JEV) or after secondary infection with a different
flavivirus.[9, 10, 13]
To overcome flavivirus cross-reactivity in diagnostics the use of recombinant antigens in
ELISA is to be preferred over whole virus as it increases specificity.[14–16] Envelope, pre M
and NS1 recombinant proteins are the most commonly used.[14–16] Of these, the NS1 has
shown to be highly immunogenic and important in the development of non-neutralizing pro-
tective antibodies.[17, 18] NS1 is thought to contain more species specific epitopes than the en-
velope protein, although some cross-reactivity is seen between NS1 proteins.[19–21] NS1 in its
natural conformation is thought to elicit a more specific immune response.[22, 23] The absence
of NS1 proteins in inactivated JEV vaccines offers further potential for serological diagnosis
through allowing differentiation between vaccinated and infected patients.[24] Thus, NS1 pro-
tein shows potential to use in serological differentiation between flavivirus infections.[25, 26]
To enable fast, syndrome based laboratory testing that focuses on multiple rather than indi-
vidual viruses, we developed a protein microarray, using recombinant NS1 proteins, as a sero-
logical test for medically important viruses within the Flavivirus genus.
Materials and Methods
Samples
Sera from anonymized patients were used for primary development of the protein microarray.
Patients were diagnosed according to international accepted criteria combining clinical symp-
toms, epidemiological data, and standard serological methods (ELISA, IFA) and laboratory
confirmed by either VNT or PCR with the exception of 10 patients suspected of JEV. Informa-
tion on each patient group used is presented in Table 1.
Protein production
Custom-made NS1 proteins produced in human embryonic kidney 293 (HEK293) cells to en-
sure proper folding, glycosylation and dimerization were used (Immune Technology Inc., New
York, NY, USA). A V5-epitope and Histag were added to the C-terminus for protein quantifi-
cation and filtration. Proteins were expressed for Dengue virus 1 (genbank:FJ687432.1), Den-
gue virus 2 (genbank:FJ744720.1), Dengue virus 3, (genbank:FJ744738.1), Dengue virus 4
(genbank:EU854300.1), Japanese encephalitis virus (genbank:NC_001437.1), St. Louis enceph-
alitis virus (genbank:ACB58159.1), Yellow fever virus (genbank:JN620362.1) and West Nile
virus (genbank:EU081844.1)
Usutu virus NS1 (genbank:NC006551.1) was produced in-house in a HEK293 cell-line. The
NS1 gene was produced by Genscript (NJ, USA) with an additional V5-epitope and Histag on
the C-terminus and cloned into a pcDNA-DEST40 vector (Invitrogen, Thermo Fisher Scientif-
ic, MA, USA) that contained a neomycine resistance gene. The vector which contained the NS1
gene was transfected into HEK293 cells. Neomycine resistant clones were selected and tested
for protein expression by immune fluorescent assay using anti-V5 monoclonal antibody. Se-
lected clones were grown in flasks and secreted NS1 protein into the medium (Opti-MEM,
Thermo Fisher Scientific, MA, USA). The secreted protein was purified from the medium by
FPLC using a Ni-NTA column (Qiagen, CA, USA) according to the
manufacturer’s instructions.
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Table 1. Overview serum collection used for ﬂavivirus microarray development.
Virus species* County of origin Number
of
samples
Days post onset
symptoms
PCR
conﬁrmed
Virus
neutralization
conﬁrmed (VNT/
PRNT)
Serology (ELISA/IFA/
Luminex)
DENV1–2 Vietnam: Hospital for Tropical
Diseases, Ho Chi Minh City,
Vietnam
19 Hospitalized patients
2–7 days post onset
symptoms
19/19 0/19 19/19
DENV1–4 Venezuela: Carabobo
University, Faculty of Science
and Technology, Department of
Biology, Venezuela
12 3–21 days post onset
symptoms
12/12 0/12 12/12
DENV1–3 Spain: National Centre for
Microbiology. Instituto de Salud
Carlos III.,Madrid, Spain
27 1–17 days post onset
symptoms with travel
history
27/27 (PCR
or NS1-
capture)
0/27 27/27
WNV Greece: Department of
Microbiology, Medical School,
Aristotle University of
Thessaloniki, Greece
7 9–23 days post onset
symptoms
0/7 7/7 7/7
WNV Netherlands: National Institute
for Public Health and
Environment, The Netherlands
5 5–21 days post onset
symptoms with travel
history
0/5 5/5 5/5
2xWNV; 1x SLEV; 1x
YFV-vac
USA: US Centers for Disease
Control and Prevention, Division
of Vector-Borne Diseases,
Arbovirus diagnostic and
reference laboratory
4 Samples were part of
the CDC 2011
reference panel for
WNV serology
0/4 4/4 4/4
JEV Vietnam: Hospital for Tropical
Diseases, Ho Chi Minh City,
Vietnam
10 From hospilized
patients with acute
encephalitis 6–18
days post onset
symptoms
0/10 0/10 10/10: serially tested by
two independent tests
(ELISA and IFA) at two
independent
laboratories**
1x JEV; 1x YFV Netherlands: National Institute
for Public Health and
Environment & Erasmus
Medical Centre, The
Netherlands
2 From hospitalized
clinical patients 5–10
post onset symptoms
with travel history
1(YFV)/2 2/2 2/2
1x pooled USUV Centro de Investigación en
Sanidad Animal, Madrid, Spain
1 Pooled rabbit sample
14 days post infection
1 /1 1/1 No tests available
2x human USUV DIMES—University of Bologna,
Unit of Microbiology, Italy
2 The only two human
encephalitis cases
reported in Europe
0/2 2/2 No tests available
Base-line group The Netherlands: National
Institute for Public Health and
Environment
82 Dutch blood donors
with unknown travel
history and
vaccination history
0/82 0/85 82/82: without detectable
antibodies to WNV,
DENV or TBEV
Vaccinated group The Netherlands: National
Institute for Public Health and
Environment & Erasmus
Medical Centre, The
Netherlands and Germany:
Centre for Biological Threats
and Special Pathogens, Robert
Koch-Institut, Germany
23 Vaccinated
individuals with
proven YFV, TBEV
and/or JEV IgG titers
0/23 19/23 23/23
(Continued)
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Microarray slide preparation
NS1 antigens at concentrations of around 2mg/ml were mixed with protein arraying buffer
(Maine manufacturing, GVS Group, Italy) and spotted in triplicate as a within-test control per
pad. Antigens were spotted onto a nitrocellulose pad coated glass slide (Maine manufacturing,
GVS Group, Italy) using a non-contact protein array spotter (PerkinElmer, Waltham, MA,
USA) as previously described.[27] Per spot two drops of 333 pL of diluted protein were used.
After printing, slides were placed in a drying chamber overnight and stored at room tempera-
ture until use.
Protocol testing for IgG and IgM antibodies
Patient sera were tested on dried slides as previously described.[27] In short, slides were incu-
bated in Blotto blocking-buffer (Thermo Fisher Scientific, MA, USA) for one hour at 37°C in
an incubation chamber to reduce non-specific binding of serum. Serum was diluted in eight
two-fold dilution steps (1:10 to 1:2560) in blotto supplemented with 0.1% Surfact-Amp
(Thermo Fisher Scientific, MA, USA) and incubated for 1 hour at 37°C in a moist chamber. In-
cubation followed with an Fc-fragment specific IgG or Fc5μ-fragment specific IgM specific
conjugate with a Cy5-fluorescent dye (Invitrogen, CA, USA) for one hour at 37°C. For IgM de-
tection, serum was first depleted of IgG antibodies using Gullsorb (Meridian Bioscience, OH,
USA) according to the manufacturer’s instructions. Between each incubation step, slides were
washed three times with a protein array washing buffer (Thermo Fisher Scientifc, MA, USA).
After final wash, slides were scanned with a Tecan scanner (Tecan Trading AG, Männedorf,
Switzerland). A median fluorescence signal (measured at 647nm) for each of the triplet spots
per antigen was determined by ScanArray Express 4.0.0.0001 supporting program (PerkinEl-
mer, MA, USA) using an adaptive circle (diameter 80–200 μm). The fluorescent signal ranged
from 0 to a maximum of 65,536 units. Results were imported in R for analysis.[28]
Protein concentration optimization
Virus antigens were spotted in serial two-fold dilutions ranging from 1:2 to 1:16 for initial
checkerboard titrations to determine optimum protein concentration as previously described.
[27] Antigens were tested using serially diluted anti-V5-epitope monoclonal antibodies (Invi-
trogen, Thermo Fisher Scientific, MA, USA). Optimum protein concentrations were defined as
those at which maximum fluorescent signal and overlapping s-curves were achieved for anti-
V5-epitope monoclonal antibodies and were found to be around 0.5 mg/ml. To minimize
Table 1. (Continued)
Virus species* County of origin Number
of
samples
Days post onset
symptoms
PCR
conﬁrmed
Virus
neutralization
conﬁrmed (VNT/
PRNT)
Serology (ELISA/IFA/
Luminex)
1x pooled JEV/DENV
negative control; 1x
pooled DENV1–4
positive control; 1x
pooled post-JEV-vac
UK: NIBSC National Institute for
Biological Standards and
Control, UK
3 International
reference samples:
reference number
#01/184, #01/186,
#01/182
3/3 3/3 3/3
* DENV1–4 = Dengue virus serotype 1 to 4; JEV = Japanese encephalitis virus; SLEV = St. Louis encephalitis virus; TBEV-vac = Tick-borne encephalitis
vaccinated; USUV = Usutu virus; WNV = West Nile virus; YFV = Yellow fever virus; YFV-vac = Yellow fever virus vaccinated;
** Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam and National Institute for Public Health and Environment, the Netherlands
doi:10.1371/journal.pntd.0003580.t001
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batch-to-batch variations each batch was tested with a serial dilution of anti-V5 monoclonal
antibodies. If a variation of more than 10% was found in reference to the initial test batch the
slides were excluded. Day-to-day variations were monitored by including a positive and nega-
tive WHO DENV1–4 reference serum during each test round. If a dilution-step difference of
more than one titer was detected results were excluded.[29]
Analysis
A script was written in R[28] using additional package ‘drc’ version 2.3–7[30], as previously de-
scribed.[27] The median fluorescent signals were converted into fitted dilution-s-curves per
protein for each serum sample. Additional script was written that allowed titers to be calculated
on the estimated s-curve at a given ROC calculated cut-off. Optimal signal cut-offs were deter-
mined by a log2 transformation of signals to further reduce variance caused by day-to-day and
slide-to-slide variations. Optimal signal cut-offs were achieved by selecting the highest possible
combination of sensitivity and specificity through ROC optimal curve calculations performed
in GraphPad Prism.[31] Titers were defined as the highest serum dilution with a signal above
the cut-off determined by ROC analysis. Heat maps were generated using an additional R pack-
age ‘stats’[28] and based on pairwise correlation between rows and columns. Mann-Whitney
tests were employed to establish the significance of differences between groups.
Accession numbers
Dengue virus 1 (genbank:FJ687432.1), Dengue virus 2 (genbank:FJ744720.1), Dengue virus 3,
(genbank:FJ744738.1), Dengue virus 4 (genbank:EU854300.1), Japanese encephalitis virus
(genbank:NC_001437.1), St. Louis encephalitis virus (genbank:ACB58159.1), Yellow fever
virus (genbank:JN620362.1) and West Nile virus (genbank:EU081844.1), Usutu virus NS1
(genbank:NC006551.1).
Results
Sensitivity and specificity for individual antigens
The mean antigen reactivity by NS1 proteins in 1:10 to 1:80 start dilutions was high in homolo-
gous DENV, WNV, JEV, SLEV, YFV and Usutu virus (USUV) positive control sera and low in
negative control sera and in sera from individuals vaccinated for JEV, TBEV or YFV (p<0.01)
with the exception of YFV NS1 antigen with YFV vaccinees (Fig. 2, Fig. 3, and Table 2). Only
some NS1 reactivity was observed in samples from blood donors for other antigens (1%).
At low serum dilutions, some patients showed antibody IgG reactivity to multiple antigens,
and therefore ROC curves were calculated in multiple dilutions and the signals for the 1:20 di-
lutions were used for signal cut-off calculations. The 1:10 and 1:20 serum dilutions produced
comparable results in sensitivity and specificity, but with significantly lower background for
the 1:20 dilutions. At 1:40 serum dilutions, the sensitivity started to decrease.
Only 13 DENV positive patients (travelers) had known primary DENV infections with a
PCR confirmed serotype (DENV1–3). All other patients with PCR confirmed DENV (serotype
1–4) were from DENV endemic countries and could not be confirmed as primary infections.
As not all DENV infections were known to be primary, the highest signal to DENV1–4 NS1
was used for calculation of the DENV cut-offs. The optimal cut-off for all proteins was around
a fluorescent signal of 15,000 for IgG and 4,000 for IgM, producing sensitivity and specificity of
86% to 100% (Table 3).
For USUV, SLEV and YFV only one or two positive patient samples were available so that
proper ROC curves could not be calculated, but background signals were in the same range as
AMultiplex Flavivirus Specific Serological Protein Microarray
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for the other antigens (Table 2). Serum samples from YFV-vaccinees were strongly positive for
YFV. Some blood donors had YFV signals above the cut-off, probably reflecting vaccination
history (Fig. 2).
Cross-reactivity
In order to study cross-reactivity within and between serocomplexes, serum samples were seri-
ally diluted and titers were calculated in R. Typical individual patient profiles are shown in
Fig. 4. To quantify the degree of cross-reactivity, the ratio of the signal for each antigen to the
maximum signal measured for that serum (typically the homologous antigen) was calculated
(Fig. 5). With one exception for IgG (serum sample #4), all patients had the highest IgG and
IgM reactivity with the homologous NS1 antigen. High level IgG reactivity to a second antigen
was observed for two of the DENV patients (against WNV and JEV, respectively) and for 2
JEV patients (against DENV) (Fig. 5a). One serum sample from a JEV patient (serum sample
4) had a higher titer DENV NS1 in comparison to JEV NS1. For IgM, only homologous reactiv-
ity was observed.
Fig 2. IgG fluorescent intensity (measured at 647nm) to flaviviruses in serum samples from clinical patients, persons vaccinated with YFV, JEV or
TBEV and healthy blood donors in a 1:20 serum dilution.NS1 proteins were spotted in a 0,5mg/ml concentration. Y axis represents the fluorescent
intensity. The median signal is depicted as a line. The dotted line represents the calculated cut-off by the ROC used to determine antibody titers.
doi:10.1371/journal.pntd.0003580.g002
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Serotype specific reactivity for DENV
IgG profiles from individual patients were combined into a heatmap (Fig. 6) to confirm group-
ing according to exposure history. One group of patients (indicated by a star in the heatmap)
showed high titers to multiple DENV serotypes. A larger group had highest titers to a single
DENV serotype, suggesting serotype specificity of the antibody array results. As most patients
were from different regions, the data were stratified for non-endemic (travelers) and multiple
DENV endemic countries. This showed a significant difference in titers between groups
(p<0.01) for IgG but not for IgM (p = 0.25) titers.
For 13 known primary DENV cases, the serotype had been determined by RT-PCR. All but
one serum had highest IgG antibody levels to the infecting serotype, but IgM antibody reactivi-
ty was lower and less discriminatory.
Discussion
We developed a first generation protein microarray for rapid, multiplex and virus-specific IgM
and IgG tests for diagnosis of flavivirus infections that could differentiate between virus species,
even within flavivirus serocomplexes, as well as between vaccinated and infected individuals,
Fig 3. IgM fluorescent intensity (measured at 647nm) to flaviviruses in serum samples from clinical patients, persons vaccinated with YFV, JEV or
TBEV and healthy blood donors in a 1:20 serum dilution.NS1 proteins were spotted in a 0,5mg/ml concentration. Y axis represents the fluorescent
intensity. The median signal is depicted as a line. The dotted line represents the calculated cut-off by the ROC used to determine antibody titers.
doi:10.1371/journal.pntd.0003580.g003
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with the exception of YFV vaccinated individuals. Initial validation shows that this microarray
can be used for flavivirus surveillance in travelers and potentially in regions with co-circulation
of multiple flaviviruses. To establish this we first investigated the sensitivity of NS1 antigens to
their homologous sera on a protein microarray. The results show good IgG and IgM sensitivity
for both JEV and DENV serocomplex viruses. The sensitivity is comparable to current IFA and
ELISA commercial kits. However, our sample selection was tested with a multitude of standard
serological assays. Comparing our results to commercial ELISA or IFA kits should therefore be
done with caution. Our results confirm that NS1 provides a good sensitive and specific antigen
tool for serological diagnosis.
For DENV, the sensitivity of the IgM assay was lower than for IgG. There are several possi-
ble explanations for this finding. First, lower DENV IgM sensitivity may have resulted because
Table 2. Median signal and 25–75% percentile for IgG and IgM per virus antigen test group.
Serum dilution 1:20 IgG 1:20 IgM 1:20 IgG 1:20 IgM
VIRUS Median 25–75%
percentile
Median 25–75%
percentile
CONTROL Median 25–75%
percentile
Median 25–75%
percentile
Dengue 65,535 65,535 17,421 8,487–46,244 Vaccinated 3,440 2,105–5,070 1,387 536–1,876
Blood
donors
4,057 3,350–4,880 1,632 1,181–1,984
West Nile 65,535 24,350–65,535 7,311 4,678–48,174 Vaccinated 2,382 1,742–3,026 542 478–972
Blood
donors
3,861 3,025–4,471 817 591–1,456
Japanese
encephalitis
65,535 65,535–65,535 23,364 65,04–37,139 Vaccinated 2,138 1,559–2,792 529 410–921
Blood
donors
2,945 2,368–3,563 806 568–1,527
Usutu 43,939 22,342–65,535 NA NA Vaccinated 2,804 1,961–3,101 ND ND
Blood
donors
3,382 2,778–4,008 809 594–1,848
Yellow fever 30,680 30,680–30,680 NA NA Vaccinated 65,535 6,5535–6,5535 NA NA
Blood
donors
11,925 9,497–13,576 3,163 1,346–4,160
St. Louis
encephalitis
65,535 65,535–65,535 NA NA Vaccinated ND NA NA NA
Blood
donors
4,808 3,636–5,649 878 711–1,084
ND = Not done; NA = Not available; Vaccinated = Vaccinated for TBEV, YFV and/or JEV
doi:10.1371/journal.pntd.0003580.t002
Table 3. Sensitivity and speciﬁcity for each virus antigen group with 95% CI.
Group n samples Sens IgG Spec IgG (n82) n samples Sens IgM Spec IgM (n80)
DENV 57 0.92 (0.93–0.98) 0.99 (0.95–1.00) 36 0.86 (0.71–0.95) 0.98 (0.93–1.00)
WNV 14 0.86 (0.57–0.98) 1.00 (0.97–1.00) 13 0.85 (0.55–0.98) 0.99 (0.95–1.00)
JEV 11 1.00 (0.72–1.00) 1.00 (0.97–1.00) 11 0.91 (0.59–1.00) 0.99 (0.95–1.00)
The number of positive samples are indicated in column ‘n samples’ and the number of negative samples are shown behind brackets in the
‘Spec’ column.
n samples = number of positive samples used; Sens = sensitivity; Spec = speciﬁcity
doi:10.1371/journal.pntd.0003580.t003
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five to ten days post onset of symptoms may be too early for detecting seroconversion in serum
samples.[32] Evaluations of commercial flavivirus IgM diagnostics kits showed varying sensi-
tivities ranging from 58% to 98%, partially due to sample timing.[32–34] Five days post onset
of symptoms, around 50–80% of patients on average have detectable IgM antibodies. This in-
creases to 99% 10 days post onset of symptoms.[35]
Fig 4. Representative examples of IgG antibody profiles of individual patients infected with JEV and DENV serocomplex viruses. Antibody profiles
are presented as titers (y-axis) for each NS1-protein (x-axis).
doi:10.1371/journal.pntd.0003580.g004
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Second, a study of antibody reactivity to individual DENV proteins has found that the mea-
sured mean OD is lower for NS1 compared to E-protein with many samples clustering closer
to the cut-off compared to E-protein antibodies.[18] This makes NS1 antibody detection more
susceptible to timing of sample taking and detection limit of test used.
Third, patient-to-patient variation in antibody responses to individual viral antigens may
cause discrepancies of test results. NS1 based protein assays could potentially pick up infections
missed by prM-E based front-line serological tests.[20] Antibodies to envelope protein were de-
tected in 91% of the DENV cases while NS1 antibodies were detected in 99%, indicating that
Fig 5. Analysis of cross-reactivity for microarray based flavivirus serology. To visualize the cross-reactivity seen in individual serum samples the
maximum calculated titer per sample was set at 100% and all other signals were expressed as a percentage of the highest titer (0–100% on y-axis).
doi:10.1371/journal.pntd.0003580.g005
AMultiplex Flavivirus Specific Serological Protein Microarray
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Fig 6. Heatmap of patient IgG antibody profiles. To visualize the overall cross-reactivity seen in individual serum samples the maximum calculated titer
per sample was set at 100% and all other signals were expressed as a percentage of the highest titer and placed in a heatmap. White refers to a titer of 0% in
reference to highest calculated titer per serum sample with a sliding scale to red which indicates a titer of 100% comparable to highest titer calculated. The
numbers alongside the patient group column correspond to the serum samples shown in Fig. 4A and 4C. The star indicates a group of patients with high titers
to multiple DENV NS1 antigens.
doi:10.1371/journal.pntd.0003580.g006
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NS1 has a higher sensitivity.[18] Two of the nine DENV IgM positive samples from travelers
that tested negative on DENV IgG ELISA, which is based on the prM-E antigen, tested IgG
positive on our microarray, further supporting this assumption.
Finally, a number of the DENV cases may have been secondary, tertiary or quaternary infec-
tions. Several of the samples originated from DENV hyperendemic countries and showed high
titers to multiple DENV and other flaviviruses, further supporting this assumption. Literature
shows that IgM antibody titers produced during a secondary DENV infection are absent or
lower and produced during a shorter period. This reduces the sensitivity of IgM antibodies in
non-primary infections significantly.[35] Despite the above limitations, the NS1-based protein
microarray performed well. Ideally, further validation is needed with sequentially sampled pa-
tient sera, allowing evaluation optimization of timing of sampling during infection, in relation
to cut-off chosen.
The biggest challenge of current flavivirus serodiagnostics is virus specific differentiation.
[3, 4] We analyzed the signals produced towards all antigens per sample to test our protein mi-
croarray’s capability to achieve this. With three exceptions (probable secondary infections),
clear differentiation of antibody responses to the homologous antigen (defined as the virus the
patient was confirmed infected with) was found for most patients. This can be clearly seen in
the heatmap (Fig. 6). This is a big advantage over currently available serological tests, for which
particularly flavivirus vaccination causes extensive cross-reactivity, mainly for IgG.[9–12] Pre-
vious epitope analysis of DENV NS1 and envelope protein indicated that NS1 has more virus
specific epitopes and thus could be used for more specific serological tests.[16, 19–22] Our re-
sults support this showing good specificity for the NS1-based protein microarray.
The cause of the outliers shown in Fig. 5 is unclear as they may be the result of cross-reactive
antibodies or previous exposure. Cross-reactive antibodies to NS1 proteins have been detected
in previous studies, but why they are seen in some patients and not others remains unclear.[20]
The reactivity to multiple antigens more likely reflects differences in exposure history.[10, 36]
This assumption is supported by the fact that most patients with reactivity to multiple antigens
originated from countries where multiple flaviviruses are endemic (Vietnam and Venezuela).
The IgG titers of these patients are log multiplications higher than singular reactive titers and
their corresponding IgM titers, which is highly indicative for secondary and frequent flavivirus
infections.[16] Distinguishing primary from secondary or multiple flavivirus infections is sero-
logically difficult.[16] Further investigation into patients with known multiple flavivirus infec-
tions will be needed to further define the uses of our multiplex array testing in such
patient populations.
While we show excellent discrimination in antibody responses to viruses within the JEV
complex, this is less straightforward for DENV. The protein microarray IgG antibody reactivity
to individual DENV NS1 antigens shows capability to distinguish serotypes (as can be seen in
Fig. 6), but this is not seen to the same extent for IgM antibodies. This was surprising as flavivi-
rus IgM envelope antibodies are thought to be more specific than IgG antibodies.[16] However,
to what extent this can also be said for NS1 is unclear. Here, future work will focus on more ex-
tensive evaluation, for which well characterized patient cohorts are needed.
Finally, we looked at the ability to rule out false positive reactions due to vaccination. This
was not possible for YFV vaccination when testing against YFV NS1. YFV vaccine is a live at-
tenuated vaccine and causes mild infection resulting in NS1 antigen and antibody production.
[37] We do, however, show that when using NS1 antigens the cross-reactivity between the YFV
serocomplex and other serocomplexes is absent.[9, 10, 13] JEV vaccine currently on the Euro-
pean and American market is an inactivated whole virus vaccine based on JEV virions.[38]
This production technique makes NS1 a good target for vaccination versus infection differenti-
ation and is the basis for current surveillance programs in Japan and surrounding countries.
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[39] However, live-attenuated (non-recombinant) JEV SA-14–14–2 vaccine is currently in use
in a number of countries in Asia and has recently been WHO prequalified. Its use nullifies the
ability to differentiate vaccination from infection, reducing public health surveillance options.
New vaccine methods using chimeric virus vaccines are in development and might provide
new opportunities for vaccination and infection differentiation through NS1. In veterinary vac-
cine development, good practice ensures the ability for such discrimination through the devel-
opment of marker vaccines according to the DIVA (Differentiating Infected from Vaccinated
Animals) principle.[40] Public health challenges associated with inability to reliably provide
patient diagnostics in some instances due to vaccination, highlight the need for introducing
this principle to the human vaccine market.
Conclusion
Serological differentiation between flaviviruses and the false-positive results caused by vaccina-
tion are a serious problem for surveillance and diagnostics of flaviviruses. Analysis of our NS1-
based protein microarray results showed a high IgG and IgM sensitivity and specificity for indi-
vidual antigens even within the same serocomplex, and limited cross reactivity. In addition, the
serology based on this array allowed discrimination between infection and vaccination re-
sponse for JEV vaccine, and no cross-reactivity with TBEV and YFV vaccine induced antibod-
ies when testing for antibodies to other flaviviruses. Based on this data, our multiplex NS1-
based protein microarray is a promising tool for surveillance and diagnosis of flaviviruses.
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